Intranasal COVID-19 vaccines: From bench to bed

Aqu Alu,1 Li Chen,1 Hong Lei Yuquan Wei Xiaohe Tian,* and Xiawei Wei*  
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China

Summary  
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. However, vaccination today failed to prevent the virus infection through the upper respiratory tract, which is partially due to the absence of mucosal immunity activation. Despite the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the next generation of COVID-19 vaccine is in demand and intranasal (IN) vaccination method has been demonstrated to be potent in inducing both mucosal and systemic immune responses. Presently, although not licensed, various IN vaccines against SARS-CoV-2 are under intensive investigation, with 12 candidates reaching clinical trials at different phases. In this review, we give a detailed description about current status of IN COVID-19 vaccines, including virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines. The ongoing clinical trials for IN vaccines are highlighted. Additionally, the underlying mechanisms of mucosal immunity and potential mucosal adjuvants and nasal delivery devices are also summarized.

Introduction  
COVID-19 pandemic caused by SARS-CoV-2 is detrimental to global health owing to its quick spread and high mutation rate, highlighting the importance of effective vaccines to prevent further morbidity and mortality. Currently, over 500 vaccines are under development, with over 150 candidates under clinical evaluation and 24 vaccines authorized for use in humans.1–3 SARS-CoV-2 is a typical mucosal pathogen that spreads from person to person via respiratory droplets.4 It infects human epithelial cells in the respiratory tract by binding to angiotensin-converting enzyme 2 (ACE2) receptors through viral spike (S) receptor-binding domain (RBD).5 Mucosal immunity is essential for adequate and long-term protection against viral infection.6 All the licensed COVID-19 vaccines are administered via intramuscular (IM) injection, which are ineffective in inducing mucosal immunity. Alternatively, mucosal immunization has the potential to induce both mucosal and systemic immune responses. Nine mucosal vaccines have been approved for humans against various mucosal pathogens, including eight orally and one intranasally (IN) administered vaccines, all of which belong to whole virus vaccines.4,7 IN vaccines are highly attractive without the requirement of needles. The significant advances of subunit protein vaccines and virus-vectored vaccines have been translated into IN vaccines of SARS-CoV-2 in preclinical and clinical settings.

Some reviews have covered the development of IN COVID-19 vaccines,4,8,9 but most of the information was outdated and incomplete considering current momentum in vaccine development. The latest review by Chavda et al. only introduced some representative IN vaccines under clinical evaluation.9 Since most clinical trial data are yet to be released, preclinical studies are essential for us to explore about the immunogenicity and safety of IN COVID-19 vaccines. This review gives a comprehensive and state-of-the-art summary of recent advances in the development of IN COVID-19 vaccines, including vaccines in research stage and under clinical trials. We also introduced mucosal immunity to help readers understand how IN vaccines work. Finally, to facilitate clinical translation, we discussed IN vaccines’ potential adjuvants and delivery systems. We hope this review will provide researchers with a comprehensive understanding of this field and inspire the future development of novel IN vaccines.

Mucosal immunity  
Mucosal immunity is a complex network composed of tissues, non-lymphoid cells, lymphocytes, and effector molecules (e.g., cytokines, chemokines, and antibodies).10 Generally, conventional injection vaccines are poor inducers of mucosal immunity, whereas IN vaccines are effective in inducing mucosal responses through nasal or oral mucosal immunization.
Immunization can induce strong mucosal immunity to avoid the entry and development of mucosal pathogens (Figure 1). When SARS-CoV-2 enters the nasal cavity, the respiratory epithelial layer becomes the first barrier against viral infection. Then, the innate immunity components in the upper airway mucosa become the first line of defense, which consist of diverse immune cells, including phagocytic neutrophils, macrophages, dendritic cells (DCs), natural killer cells, and mast cells. These immune cells can form an integrated system to directly fight against pathogens or induce adaptive mucosal immunity via multiple mechanisms. If the viruses reach deeper airways or lungs, pathogens-associated molecular patterns (PAMPs) expressed on viruses will be recognized by pattern recognition receptors (PRRs) expressed in respiratory epithelial cells, DCs, and alveolar macrophages. Viral particles are degraded by endosomal enzymes and release single-stranded RNA that can be recognized by toll-like receptor (TLR) 7 or TLR8. Activation of the PRRs leads to increased expression of proinflammatory cytokines such as type I interferon (IFN-I). IFN-I and IFN-III play significant roles in fighting against viral infection at early stages. However, SARS-CoV-2 infection induces a lower level of IFN-I and IFN-III than other respiratory viruses. Additionally, the complement system is a crucial component of innate immunity against SARS-CoV-2, which should be considered when designing antibody-based therapeutics and vaccines against SARS-CoV-2.

Mucosal immunization can induce extensive adaptive immune responses, characterized by mucosal secretory IgA (sIgA) antibodies and resident memory T (T<sub>RM</sub>) cells. Mucosal sIgA can be divided into dimeric,
trimeric, tetrameric, and larger polymeric IgA (pIgA), in contrast to monomeric IgA in serum. Dimeric sIgA is the primary effective form of mucosal sIgA. The identified sIgA inductive sites include nasopharynx-associated lymphoid tissue (NALT), isolated lymphoid follicles, and mesenteric lymph nodes. NALT serves as the key site in inducing mucosal immune responses, where Th1- and Th2-polarized lymphocytes, and IgA-secreting B cells are generated. slgA antibodies neutralize toxins or pathogens in the mucosa through three pathways: immune exclusion, antigen excretion, and intracellular neutralization. Intriguingly, mucosal sIgA levels increase promptly in infants and reach adult levels early in childhood, while serum IgA matures much slower and may not reach adult levels until puberty. Given the apparent differences in the susceptibility of children and adults to COVID-19, this difference should be taken into consideration in vaccine development. 

TRM cells in the airways and lungs are vital for preventing respiratory virus infection. TRM cells confer rapid response upon restimulation with viral antigens, which induce the production of inflammatory cytokines to mediate tissue antiviral resistance and chemokines to recruit auxiliary immune cells. It is demonstrated that lung TRM cells provide stronger protective immunity than circulating T cells. IN vaccination effectively induces the generation of TRM cells, and persistent antigen present in the lungs can promote long-term maintenance of TRM cells. In the lungs, TRM cells can further migrate to mediastinal lymph nodes through ‘retrograde migration’ process to maintain TRM cell phenotype and offer long-term immunity. CD8+ TRM cells are vital for direct protection against respiratory viral infection. It is indicated that a combination of mucosal prime and systemic booster vaccinations can enhance the longevity of lung CD8+ TRM cells. CD4+ TRM cells are required to help guide the formation of protective CD8+ TRM cells and B cells. The efficacy of IN vaccines is significantly elevated owing to their capacity of inducing TRM cells in the respiratory system.

Recent progress in the development of intranasal COVID-19 vaccines

Recent studies indicate that IM vaccines are poor in controlling viral replication and nasal shedding in the upper respiratory tract, leading to asymptomatic or milder symptomatic infection that can still transmit virus to others. In contrast, IN vaccines have the potential to induce sterilizing immunity against mucosal pathogens (Figure 2). Antigens are exposed at the initial site of viral attack to induce potent immune responses at local or distant mucosa. Meanwhile, the systemic humoral and cellular immunity triggered by IN administration is comparable to or stronger than that induced by IM injection, suggesting a lower dose required to increase vaccine safety. For instance, IN immunization with a chimpanzee adenovirus (Ad)-vectored SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S) induced higher levels of S-specific neutralizing antibodies in hamsters compared to IM route. In addition, IN immunization can induce pan-reactive antibodies, which is particularly attractive owing to the increase in COVID-19 variants.

The development of IN vaccines also brings huge socio-economic value. In a global scale pandemic, such as COVID-19, immunizing whole populations as quickly as possible can be achieved through IN vaccines as they do not require to be administered by healthcare professionals, leading to higher patient compliance. The fact that these are often delivered through nasal devices makes them a better alternative for individuals who are not keen on needle injections, particularly children. Another advantage of IN vaccines is that they do not require a sterile environment for administration which benefits vaccination programs in countries with fewer resources. Moreover, IN delivery can avoid risks associated with improper use of needles, such as transmitting blood-borne diseases like hepatitis B (HBV) and human immunodeficiency virus (HIV). For these reasons, scientists are making great efforts in developing IN COVID-19 vaccines.

The major challenge in developing IN vaccines is to deliver the antigens to antigen-presenting cells (APCs) presented in the respiratory tract while overcoming nasal clearing. As described in earlier sections, the epithelial layer traps viral particles and removes them from the body. Hence, the antigen used in the vaccine must remain in the respiratory tract for an adequate amount of time to allow antigen absorption, which elicits immune responses for a long time. Besides, the antigen must be stable enough to withstand the enzymatic degradation in the mucosal lining, such as the azoreductase-mediated degradation. A common approach to overcome such obstacles is to turn into vaccine formulations, such as the use of adjuvants and delivery systems, to prolong the time in which the antigen remains in the mucosal lining while enhancing its stability.

Although the first IN vaccine is yet to be approved for human use at the time of writing, 12 nasal vaccines have entered different stages of clinical trials. Here we gave a comprehensive introduction about current preclinical (Table 1) and clinical (Table 2) studies of IN COVID-19 vaccines.

Virus-vectored vaccines

Preclinical studies. Adenovirus-vectored vaccines. Wu et al. firstly demonstrated that IN vaccination with a replication-defective Ad5-vectored vaccine encoding the
Figure 2. Current progress in the development of IN vaccines for COVID-19. Different types of IN vaccines have been developed for COVID-19, including virus-vectored vaccines, protein subunit vaccines and others. Virus-vectored IN vaccines are under most intensive investigations, especially adenovirus-vectored vaccines. IN vaccines can induce strong immune responses against SARS-CoV-2, including mucosal (sIgA), humoral (IgM, and IgG), and cellular immune responses, which can protect immunized animals or humans against SARS-CoV-2 infection and transmission. Created with BioRender.com.
| Type                          | Vaccine                              | Target       | Route (no. of doses) | Animal used                        |
|-------------------------------|--------------------------------------|--------------|----------------------|------------------------------------|
| Ad-vectored vaccine          | ChAd-SARS-CoV-2-5                    | S protein    | IN (1)               | hACE2 mice<sup>16,17</sup> and rhesus macaques<sup>18</sup> |
|                              | ChAd-SARS-CoV-2-5                    | S protein    | IM or IN, (1)        | Golden Syrian hamsters<sup>19</sup> |
|                              | Ad5COVID                             | RBD protein  | IN (1)               | Mice<sup>20</sup>                  |
|                              | Ad5.SARS-CoV2-S1                     | S1 protein   | IN or SC, (1)        | Mice<sup>21</sup>                  |
|                              | ChAdOx1                              | S protein    | IM or IN, (1 or 2)   | Ferrets<sup>22</sup>, hamsters and rhesus macaques<sup>23</sup> |
|                              | Ad5-nCoV                             | Full-length S protein | IM or IN, (1); or oral + IN, simultaneously, (1) | Mice and ferrets<sup>24</sup> |
|                              | Ad5-S-nb2                            | S protein    | IM or IN, (1)        | Mice and rhesus macaques<sup>25</sup> |
|                              | Ad5-NC                               | N protein    | IN (2)               | Mice<sup>26</sup>                  |
|                              | AdC7-S, AdC7-RBD and AdC7-RBD-tr2    | S, RBD or tandem-repeat dimeric RBD | IM or IN, (2) | hACE2 mice<sup>27</sup> |
|                              | —                                    | S and N proteins | SC or IN, (1) | Mice<sup>28</sup> |
|                              | —                                    | S protein    | IP + IN (2); or IM + IN (2) | Mice and golden hamsters<sup>29</sup> |
|                             | Lentivirus-vectored vaccine          | ΔNA(RBD)-Flu virus | RBD protein | hACE2 mice<sup>30</sup> |
|                             | Influenza virus-vectored vaccine     | scPR8-RBD-M2 | SARS-CoV-2 RBD and influenza matrix 2 protein | IN + IN or IN + IM, (2) | Mice<sup>31</sup> |
|                             | PIV5-vectored vaccine                | CVVGA1       | S protein | IN (1) | K18-hACE2 mice and ferrets<sup>32</sup> |
|                             | hPIV2-vectored vaccine               | BCPV/S-2PM   | S protein | IN (1 or 2) | Mice and golden hamsters<sup>33</sup> |
|                             | NDV-vectored vaccine                 | AVV/COVID-12-HEXAPRO | S protein | IN + IM, IM + IM, or IN + IM, (2) | Mice, hamsters<sup>34</sup>, and pigs<sup>35</sup> |
|                             | NDV-FLS                             | S protein    | IN (1 or 2)          | Hamsters<sup>36</sup> |
|                             | nNDV-S                              | S protein    | IN (2)               | Mice and hamsters<sup>37</sup> |
|                             | VSV-vectored vaccine                 | rVSV/SARS-CoV-2 | S protein | IN or IM, (1) | Normal/hACE2 mice, and rhesus macaques<sup>38</sup> |
|                             | VSV-SARS2-EBOV                       | SARS-CoV-2 S protein and/or the EBOV glycoprotein | IM or IN, (1) | Hamsters<sup>39</sup> and rhesus macaques<sup>40</sup> |
|                             | Virus like particles                 | RBD protein  | IM alone or IM + IN, (3) | Ferrets<sup>41</sup> |
|                             | Live-attenuated vaccine              | SARS-CoV-2/ human/Korea/ CNJUV03-C22 °C /2020 | IN spray (1) | hACE2 transgenic mice<sup>42</sup> |
|                             | Bacterium-vectored vaccine           | M and N proteins | ID or IN, (2) | Syrian golden hamsters<sup>43</sup> |
|                             | Protein subunit vaccine              | LP18:RBD     | RBD                  | Mice<sup>44</sup> |
|                             |                                      | RBD protein  | IN (2)               | Mice<sup>45</sup> |
|                             |                                      | S1 protein   | IM (3) or IN (4)     | Rhesus macaques<sup>46</sup> |
|                             |                                      | RBD protein  | IM or IM, (3)        | Mice<sup>47</sup> |
|                             |                                      | S1 protein   | IN (3)               | Mice<sup>48</sup> |
|                             |                                      | Trimeric or monomeric S protein | IN (1) | Mice<sup>49</sup> |
|                             | DNA vaccine                          | pQAC—CoV; MVA-CoV | S and N proteins | IN or IM, (3), or IN (2) | Mice<sup>50</sup> |
|                             |                                      | S protein    | IN                  | Mice<sup>51</sup> |

Table 1: Preclinical studies of IN COVID-19 vaccines.
PIV: parainfluenza virus; NDV: Newcastle disease virus; VSV: vesicular stomatitis virus; EBOV: Ebola virus; MVA: Modified Vaccinia Ankara.
| Type                  | Vaccine               | Developer/manufacturer                      | Nasal delivery device                        | Phase | Status                  | Enrollment | Clinical trial No. | Route          |
|----------------------|-----------------------|--------------------------------------------|----------------------------------------------|-------|-------------------------|------------|-------------------|----------------|
| Ad-vectored vaccine  | Ad5-nCoV              | CanSino/Beijing Institute of Biotechnology | Aerogen Ultra Device                         | I     | Active, not recruiting  | 149        | NCT04552366       | IN, IM or IN+IM |
|                      |                       |                                            | I/II Recruiting                              |       |                         | 840        | NCT04840992       | IM or IN       |
| ChAdQx1              | AstraZeneca/University of Oxford | MAD Nasal™ Intranasal Mucosal Atomization Device | I     | Enrolling by invitation | 54     |                     | NCT04816019 | IN              |
| BBV154               | Bharat Biotech International Limited | N/A                                       | I     | Active, not recruiting  | 175   |                     | NCT04751682 | IN              |
| SC-Ad6–1             | Tetherex Pharmaceuticals Corporation | N/A                                       | I     | Recruiting              | 80    |                     | NCT04839042 | IM or IN        |
| NDV-vectored vaccine | AdCOVID               | Alimmune, Inc.                             | Pipette droppers                             | I     | Not processing          | 180        | NCT04679909       | IN              |
|                      | AVX/COVID-12-HEXAPRO  | Laboratorio Avi-Mex, S.A. de C.V.          | An automatic syringe (Prima mist sprayer)    | I     | Recruiting              | 90         | NCT04871737       | IN, IM or IN+IM |
| LAIV-vectored vaccine| DelNS1 – 2019-nCoV-RBD-OPT1 | University of Hong Kong, Xiamen University and Beijing | Spray devices                              | I     | Complete                | 60         | ChiCTR2000037782   | IN              |
|                      |                       | Wantai Biological Pharmacy                 |                                               | II    | Complete                | 720        | ChiCTR2000039715   | IN              |
|                      |                       |                                            |                                               | III   | –                       | 40,000     | ChiCTR21000051391  | IN              |
| PIVS-vectored vaccine| CVXGA1                | CyanVac LLC                                 | Spray devices                              | I     | Not recruiting          | 80         | NCT04954287       | IN              |
| RSV-vectored vaccine | MV-014–212            | Meissa Vaccines, Inc.                      | Droppers or spray devices                    | I     | Recruiting              | 130        | NCT04798001       | IN              |
| Protein subunit vaccine| CIGB-669              | CIGB                                       | Syringe-based spray devices                  | I/II  | Pending                 | 88         | RPCEC00000345      | IN alone or IM+IM |
|                      |                       |                                            |                                               |       |                         |            |                   |                 |
| Razi Cov Pars        | Razi Vaccine and Serum Research Institute | Spray devices                              | I     | Complete                | 133   |                     | RCT2020121409709N1 | IM + IN |
|                      |                       |                                            |                                               | II    | Complete                | 500        | RCT2020121409709N2 | IM + IN |
|                      |                       |                                            |                                               | III   | –                       | 41,128     | RCT2021020650529N3 | IM + IN |
| Live attenuated vaccine| COVI-VAC              | Cadenosin, Inc.                            | Droppers                                    | I     | Active, not recruiting  | 48         | NCT04619628       | IN              |

Table 2: Clinical trials of IN COVID-19 vaccines.
NDV: Newcastle disease virus; LAIV: live attenuated influenza virus; PIV: parainfluenza virus; RSV: respiratory syncytial virus; N/A: Not available. Data from https://clinicaltrials.gov/, https://www.chictr.org.cn/index.aspx and https://covid-19.cochrane.org/.
full-length S protein (Ad5-nCoV) induced both systemic and local mucosal immune responses against SARS-CoV-2.35 Ferrets receiving a single mucosal (simultaneous oral and IN delivery), or IM dose of Ad5-nCoV generated high levels of serum neutralizing IgG antibodies. However, mice studies indicated that only IN vaccination can increase the generation of S-specific IgA antibodies in the trachea-lung washes. Upon challenge with SARS-CoV-2, mucosal vaccinated ferrets were immune from viral infection in the upper and lower respiratory tracts, as measured by the infectious virus and viral loads in lung and nasal turbinate, respectively. Contrarily, IM immunization showed limited efficacy in reducing the viral loads in the upper respiratory tract.

Soon after, Feng et al. demonstrated that a single IN immunization with Ad5-S-nb2 induced both systemic and local mucosal protective immunity in mice and rhesus macaques.39 Ad5-S-nb2 is a replication-incompetent Ad5-vectored vaccine encoding S1 protein of SARS-CoV-2. Notably, the preexisting anti-Ad5 immunity in humans from natural exposure or previous vaccination may compromise the efficacy of Ad5-vectored vaccines. It is reported that the existence of vector-specific serum antibodies severely hampers the seroconversion (an alteration from seronegative to seropositive state) of neutralizing antibodies against SARS-CoV-2 in IM vaccinated volunteers.40 Consistent with previous results, IN administration of Ad5-S-nb2 in macaques showed delayed increase and lower serum antibody titers against Ad5 vectors than IM dosing,40 indicating that IN vaccination may be devoid of the undesired influence caused by anti-vector immunity.

ChAd-SARS-CoV-2-S vaccine encodes a prefusion stabilized S protein of SARS-CoV-2.33,42,43 Prefusion stabilization enhances antigenicity by increasing the expression of viral fusion glycoproteins that are the targets of neutralizing antibodies.3 One IN dose of ChAd-SARS-CoV-2-S induced neutralizing antibodies and T cell responses, preventing or limiting viral infection in nasal swabs, bronchoalveolar lavage fluid (BALF), and lungs of rhesus macaques.57 IM immunization of mice expressing human ACE2 (hACE2), on the other hand, only triggered a minimal mucosal immune response and scarce antigen-specific IgA in the serum, resulting in detectable viral RNA in the lungs. Therefore, IM vaccination could only reduce, but not abrogate, lung infection. IN immunization also increased the percentage of IFN-γ-secreting CD8+ T_RM cells in the lungs, providing a first response against reinfection.39 Then, the durability and protectivity of ChAd-SARS-CoV-2-S vaccine was also evaluated.58 A single IN dose induced long-term immunity that lasted for at least nine months, with an increase in the numbers of antibody-secreting long-lived plasma cells in the bone marrow. More importantly, IN vaccination elicited excellent protectivity against mutated strains of SARS-CoV-2 (B.1.1.28 and B.1.617.1). Altimmune, Inc. developed a replication-deficient Ad5-vectored vaccine candidate encoding the RBD of SARS-CoV-2, called AdCOVID.59 A single IN vaccination with AdCOVID was reported to be highly effective in mice. Another team from the University of Pittsburgh developed an Ad5-vectored vaccine that encodes SARS-CoV-2 S1 protein.60 A single subcutaneous or IN administration of this vaccine induced robust and durable antiviral immune responses that lasted for at least 24 weeks.

Bricker et al. found that nasal shedding can only be reduced in IN immunized hamsters and rhesus macaques other than IM vaccinated ones using ChAdOx1 vaccine (an Ad-based vaccine encoding S protein of SARS-CoV-2).35,46-47 In a transmission study model, Syrian hamsters IN or IM immunized with ChAdOx1 vaccine were co-housed with unvaccinated donor animals that were pre-infected with SARS-CoV-2.64 In the transmission model, only partial protection of the lower respiratory tract was observed in IM vaccinated hamsters, whereas IN vaccination showed complete control of viral infection. It is possible that in challenge studies, a high dose of live viruses is directly sent to the lower respiratory tract by swift intratracheally or IN route, where activated systemic immunity could combat virus in the lungs. However, the transmission model simulates an actual state of natural infection, where viral infection is low-dose, persistent, and attacks the upper respiratory tract at first. In SARS-CoV-2 infected patients, it is reported that neutralizing IgA antibodies are often detectable earlier than the appearance of IgG, while mucosal IgA remains detectable for a long time.48 The neutralizing potency of IgA dimers in nasopharynx is 7.5-fold greater than IgG equivalents in the serum.49 High level of sIgA in nasal mucosa induced by IN immunization prevents SARS-CoV-2 infection and stops viral transmission, which is absent in IM immunized animals. Therefore, we can conclude that most IM administered vaccines are unable to clear subgenomic and genomic viral RNA in the upper respiratory tract, suggesting viral replication and the possibility of viral transmission.

Ad-vectored vaccines can also express S antigens with advanced structures or encode other potential antigens to enhance the magnitude and breadth of immune responses. Xu et al. developed several chimpanzee Ad-vectored COVID-19 vaccines expressing S protein (Ad-S), RBD (Ad-RBD), or tandem-repeat dimeric RBD (Ad-RBD-tr2), respectively. Compared with Ad-S or Ad-RBD, Ad-RBD-tr2 induced the highest level of antibody responses that could neutralize both wild-type and variant strains of SARS-CoV-2, especially the Delta variant.65 N protein alone, or combined with S protein, can also be the target of Ad vector-based IN vaccines, which could induce strong N- and S-specific immune responses in mice.66 Further studies are necessary to strengthen the potential of N protein as an ideal vaccine target for SARS-CoV-2.
Vaccines based on other viral vectors. Loe et al. incorporated the coding sequence of RBD into the genome of attenuated influenza virus. A single IN dose induced RBD-specific neutralizing antibodies, with titers up to 1:200 in mouse sera. However, high levels of influenza-specific neutralizing antibodies were also detected, hinting at the development of this vaccine. A single-cycle influenza virus-based vaccine (scPR8-RBD-M2) was also developed to encode SARS-CoV-2 RBD and influenza matrix 2 protein. Mice that received two doses of scPR8-RBD-M2 (IN + IN or IN + IM) elicited robust mucosal and systemic immune responses. A parainfluenza virus (PIV) 5-based COVID-19 vaccine, named CVXGA1, prevented virus infection and blocked contact transmission in K18-hACE2 mice and ferrets after a single IN dose. Non-propagative human PIV2-based IN COVID-19 vaccine (BC-PIV/S-2PM) protected the lungs from viral infection after one dose and conferred complete protection of the nasal turbinates after two doses.

A single intraperitoneal injection of a lentivirus-vectored COVID-19 vaccine decreased viral replication in the lungs of golden hamsters. Further boosting via IM route failed to improve the protection rate, whereas IN booster induced high levels of neutralizing IgG and IgA antibodies in the serum, resulting in >3 log10 decreases in lung viral loads. Therefore, an IP + IN or IM + IN prime-boost strategy may provide high prophylactic efficacy and allow sterilizing protection against SARS-CoV-2 infection. Another non-integrate lentivirus-vectored IN vaccine induced sterilizing protection of lungs and central nervous system against both the ancestral SARS-CoV-2 and its P.1 variant of concern. This vaccine is attractive owing to its protection against the mutated strains, which is the major challenge of the persistent pandemic.

Laboratorio Avi-Mex, S.A. de C.V. developed a live Newcastle disease virus (NDV)-vectored vaccine (AVX/COVID-12-HEXAPRO; Patria) that encodes prefusion stabilized S protein. It induced strong immunity against the wild-type SARS-CoV-2 and some common variants (B.1.1.7, B.1.351, and P.1) in pigs via IN and IM alone, or IN + IM immunization methods. No adverse reactions were observed at any dose level or immunization models, indicating a desirable safety profile. Similar results were also observed in mice and hamster models. It is suggested that two-dose IN immunization with NDV-vectored vaccines may induce more robust protection than single-dose. Two doses of IN and NDV-S (a recombinant NDV-based vaccine expressing S protein of SARS-CoV-2) elicited strong protective immunity and reduced viral shedding in nasal turbinates and lungs of hamsters.

A vesicular stomatitis virus (VSV)-based COVID-19 vaccine induced eight-fold higher titers of neutralizing antibodies after one single IN dose than single IM dose in macaques. Another VSV-based vaccine, which encodes SARS-CoV-2 S protein alone or with Ebola virus glycoprotein (VSV-SARS2-EBOV), induced early CD8+ T cell response after IN immunization while IM immunization tended to cause CD4+ T and NK cell responses. These results indicated the potential of VSV as an ideal IN vaccine carrier. Nevertheless, Furuyama et al.'s VSV-based IN vaccine showed no protection of nonhuman primates from viral challenge. Therefore, to enhance the efficacy, antigens should be well-designed, and the VSV vectors need to be further optimized.

Clinical trials. A total of nine IN vaccines based on viral vectors are under clinical studies. Bharat Biotech International Limited developed a replication-deficient chimpanzee Ad-vectorized vaccine that expresses stabilized S protein of SARS-CoV-2 (BBV154). BBV154 is now under a phase I randomized multicenter clinical trial involving 175 participants, who receive one or two IN doses of vaccination (NCT04751682). CanSino Biologics Inc./Beijing Institute of Biotechnology is evaluating Ad5-nCoV’s safety and immunogenicity in an open-label phase I clinical trial involving 149 participants. Participants were allocated into six groups to receive different doses of vaccination via only IN or IM routes, or combining IM prime with IN booster (NCT04552366). The Ad5-nCoV inhalation vaccine is also registered in another phase I/II clinical trial (NCT04840952) involving 840 volunteers. SC-Ad6–1, another Ad-vectorized vaccine, is being assessed in a phase I study operated by Tetherex Pharmaceuticals Corporation (NCT04839042). So Vol- unteers were administered with SC-Ad6–1 via IN or IM route to evaluate the safety, reactogenicity, and immunogenicity. The University of Oxford is evaluating the potency of IN-administered ChAdOx1 in 54 healthy volunteers (NCT04816219), which has already been approved for human use via IM injection. AlImmune, Inc. registered a clinical trial to evaluate the safety and immunogenicity of AdCOVID (NCT04679909). However, clinical trial data indicated that AdCOVID did not stimulate adequate antiviral immunity. Thus, AlImmune, Inc. declared that further development of AdCOVID will be discontinued, removing AdCOVID from the potential vaccine candidate list.

Four IN vaccines based on other viral vectors are also under clinical evaluation. The NDV-based AVX/COVID-12-HEXAPRO vaccine is administered to 90 healthy volunteers in a phase I clinical trial. Two doses of this vaccine were evaluated with three schemes of vaccination (IM and IN alone, or IN + IM) (NCT04871737). DelNSI–2019-nCoV-RBD-OPTI, a live attenuated influenza virus-vectorized vaccine targeting RBD, has completed phase I (ChiCTR2000037782) and phase II (ChiCTR2000039715) clinical evaluation in China. Results indicated that the DelNSI–2019-nCoV- RBD-OPTI vaccine is very tolerated and immunogenic in inducing the generation of mucosal IgA, systemic
IgG, and T cell responses. The promising results supported the initiation of a phase III study (ChiCTR2100013391). The PIV5-based vaccine (CVXGA1) is also under phase I clinical investigation (NCT04954287). Meissa Vaccines, Inc. developed MV-014—212 vaccine based on a live-attenuated respiratory syncytial virus (RSV), which expresses the S protein of SARS-CoV-2 (NCT04798001). 130 participants are recruited to receive single or two doses of MV-014—212 via IN drops or spray.

**Protein subunit vaccines**

**Preclinical studies.** While more tolerable, subunit vaccines are always less immunogenic due to the swift enzymatic degradation and the deficiency in stimulating APCs. One commonly accepted method to increase their immunogenicity at mucosa is to use vaccine adjuvants and delivery systems. Our team investigated the potential of different cationic nanocarriers as IN adjuvants for a recombinant RBD vaccine of SARS-CoV-2. We found out that polyethyleneimine (PEI), N-[1-(2,3-Dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTAP), and chitosan are all promising mucosal adjuvants, whereas PEI-based vaccine induced the strongest immune responses. PEI can also increase antigen uptake by APCs and promote the maturation of APCs in vitro. Jangra et al. generated an IN nanomulsion-based adjuvant for a recombinant SARS-CoV-2 S protein, which assisted in evoking strong antiviral immune responses that offered protection against both homologous SARS-CoV-2 and an N501Y mutated strain in mice.

An et al. developed an IN subunit vaccine of SARS-CoV-2 composed of trimeric or monomeric S protein which was adjuvanted with a liposomal agonist of cyclic GMP-AMP receptor stimulator interferon genes (STING). A single dose IN administration effectively induced antiviral immune responses. Moreover, the trimeric antigen was much more effective than the monomeric antigen by inducing significantly higher neutralizing IgG and sIgA titers. Single-cell RNA-sequencing confirmed the activation of T and B cells within the NALT, which is the inductive site to elicit potent and long-lasting immunity locally and systemically. Kim et al. utilized self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles to deliver a RBD protein vaccine of SARS-CoV-2. In the presence of AddaVax adjuvant (a squalene-based oil-in-water nanomulsion), IN vaccination with the RBD-ferritin nanoparticle completely protected immunized ferrets from SARS-CoV-2 challenge.

An IM prime followed by an IN booster combines the advantages of the two immunization routes. Sui et al. compared the efficacy of an S1 protein-based vaccine using IM +IM or IM +IN prime-booster vaccination regimes in rhesus macaques. The mucosal vaccine was incorporated into DOTAP or poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing CpG, poly I:C, and IL-15 adjuvants. IM boosting strategy induced strong and persistent humoral and cellular immunity, whilst IN boosting induced significantly higher dimeric IgA and IFN-α responses. After SARS-CoV-2 challenge, genomic copies in nasal swabs of the IN boosted animals were much lower than IM boosted ones, indicating the higher efficiency in the clearance of invading virus. Therefore, compared with the conventional IM-only strategy, IN booster may be a complementary reinforcement to better and complete protection against viral infection.

The mucosal immunity triggered by IN vaccines is not limited to local respiratory sites. Du et al. reported that mice IN immunized with a recombinant RBD vaccine in the presence of aluminum oxyhydroxide gel adjuvant exhibited increased RBD-specific sIgA in not only nasal mucosa, but also genital and intestine tracts. Since SARS-CoV-2 infection may result in viral shedding from feces and disturb female reproductive function, high levels of sIgA in the vagina and intestine may provide broad-spectrum protection and completely abrogate viral transmission.

**Clinical trials.** Center for Genetic Engineering and Biotechnology (CIGB) developed a protein subunit vaccine (CIGB-669) comprising of RBD protein and HBV nucleocapsid (N) antigen (AgnHB, an immunopotentiator). In a phase I/II clinical trial launched in Cuba, CIGB-669 is administered to 88 participants via IN spray alone without adjuvant or in combination with IM injection with alum adjuvant (RPCEC00000345). Razi Vaccine and Serum Research Institute also developed a recombinant S protein vaccine (Razi Cov Pars), which has completed phase I (IRCT20201214049709N1) and phase II (IRCT20201214049709N2) clinical trials and is now under phase III study (IRCT20210206050259N3) in Iran.

**Other types of IN vaccines**

**Preclinical studies.** Other COVID-19 vaccines have also been designed for IN immunization, including live-attenuated vaccines, bacterium-vectorized vaccines, and nucleic acid-based vaccines. Seo and Jang developed a cold-adapted live-attenuated COVID-19 vaccine, a single IN spray of which induced potent humoral, cellular, and mucosal IgA immune responses in K18-hACE2 mice. Immunized mice were completely protected from viral challenge without detectable viral titers in nasal turbinate and vital organs. Codagenix Inc also developed a scalable live-attenuated SARS-CoV-2...
A replicating bacterium-vectorised COVID-19 vaccine was produced using live-attenuated *Francisella tularensis subsp. holarctica* vector, LVS ΔcapB vector to express the membrane and N proteins of SARS-CoV-2. Golden Syrian hamsters intradermally or IN immunized with this vaccine were protected from live viral infection, correlated with serum anti-N antibody titers. The bacterium-vectorised vaccine is safe, inexpensive to generate, easy to be stored and distributed. Another Lactobacillus plantarum-based vaccine that expresses surface-displayed RBD of SARS-CoV-2 induced strong mucosal IgA (in respiratory and intestinal tracts) after IN immunization. Further investigation is desired to evaluate bacterium-based vaccines' immunogenicity and safety in bigger animal models to promote their clinical translation.

DNA vaccines possess several advantages including stability, durability, and ease of manufacture. Kumar et al. designed a DNA vaccine targeting the S protein of SARS-CoV-2 based on gold-nanostar-chitosan carrier. This vaccine was protected from live viral infection, correlated with serum anti-N antibody titers. The bacterium-vectorised vaccine is safe, inexpensive to generate, easy to be stored and distributed. Another Lactobacillus plantarum-based vaccine that expresses surface-displayed RBD of SARS-CoV-2 induced strong mucosal IgA (in respiratory and intestinal tracts) after IN immunization. Further investigation is desired to evaluate bacterium-based vaccines' immunogenicity and safety in bigger animal models to promote their clinical translation.

DNA vaccines possess several advantages including stability, durability, and ease of manufacture. Kumar et al. designed a DNA vaccine targeting the S protein of SARS-CoV-2 based on gold-nanostar-chitosan carrier. This vaccine was protected from live viral infection, correlated with serum anti-N antibody titers. The bacterium-vectorised vaccine is safe, inexpensive to generate, easy to be stored and distributed. Another Lactobacillus plantarum-based vaccine that expresses surface-displayed RBD of SARS-CoV-2 induced strong mucosal IgA (in respiratory and intestinal tracts) after IN immunization. Further investigation is desired to evaluate bacterium-based vaccines' immunogenicity and safety in bigger animal models to promote their clinical translation.

**Clinical trials.** COVI-VAC has been launched into a phase I clinical trial, where 40 participants are enrolled to receive one or two IN doses of vaccination (NCT04619628). Symptoms including oral body temperature and adverse events will be recorded, and some basic examinations like chest X-rays and physical exams will be performed after immunization.

**Adjuvants for intranasal vaccines.**

Due to the low affinity of most antigens with epithelium and the tight junctions between epithelial cells, antigens tend to be cleared rapidly by mucociliary removal. Therefore, vaccine adjuvants are commonly added for enhanced immunogenicity in the mucosa, especially for subunit vaccines. Adjuvants can increase the magnitude and durability of antiviral immunity and exert a dose-sparing effect. Here we briefly introduced current advances in nasal adjuvants (Figure 3).

**Toxoid adjuvants.**

Two enterotoxin-derived adjuvants, Cholera toxin (CT, with unit A and unit B) and *Escherichia coli* heat-labile toxin (LT), are used as the proof-of-concept mucosal adjuvants. They can regulate immune responses via binding to GM1 ganglioside receptors presented on the membranes of most APCs. However, their application is severely hampered by safety concerns, including Bell's palsy. Alternatively, detoxified derivatives were developed. CTA1DD is a nontoxic derivative of CT whose unit B is removed and replaced with a dimer of fragment D of protein A from *Staphylococcus aureus*. CTA1DD adjuvanted influenza vaccines effectively induced antibody responses and prevented influenza virus infection and transmission after IN immunization. LThK is a detoxified derivative of LT, which exhibits inhibited ADP-ribosylating enzyme activity. Nasal delivery of LThK did not result in redirection to central nerve system, suggesting its safety profiles. An LThK-adjuvanted influenza vaccine was reported to be remarkably effective and tolerable after two IN vaccinations in phase I (NCT03293732) and phase II (NCT03784885) clinical trials.

**Polymers.**

Polymers are promising mucosal adjuvants given their vaccine delivery capacity and immunostimulatory effects. Chitosan, a natural derivative of α-chitin, is an attractive mucosal adjuvant due to its mucoadhesive and immune-stimulatory properties. Chitosan-based nanoparticles can prolong local retention, enhance mucosal antigen absorption, and protect them from degradation in the mucosa. Chitosan can also trigger innate and adaptive immune responses via DNA sensor cGAS-STING dependent activation of APCs. Mice IN immunized with chitosan-adjuvanted influenza vaccines induced strong antiviral immunity and conferred complete protectivity against homologous and heterologous influenza virus challenge. Chitosan-adjuvanted inactivated mutant diphtheria toxoid CRM197 vaccine also generated high levels of neutralizing antibodies in humans after IN immunization. Volunteers that received two doses of norovirus vaccine, which was adjuvanted by monophosphoryl lipid A (MPL) and chitosan, showed no signs of vaccine-related serious adverse events (NCT00806962) and induced strong antigen-specific humoral responses (NCT00973284).

PEI, a synthetic cationic polymer widely used as a gene transduction agent, is also an excellent adjuvant for IN vaccines. Current application of PEI as mucosal
Figure 3. A schematic illustration of mucosal adjuvants for IN vaccines. Created with BioRender.com.
Adjuvant is limited to experimental researches owing to its safety concerns in humans.\(^{6,9,95}\) IN administration of mice with PEI-adjuvanted RBD vaccine induced high titers of neutralizing antibodies against SARS-CoV-2.\(^{69}\) A single IN dose of subunit glycoprotein antigens with PEI evoked robust antibody-mediated protection from lethal challenge of influenza or herpes simplex virus type-2 (HSV-2), superior to conventional CT adjuvant.\(^{96}\) PEI could form a nanoscale complex with protein antigens which can be quickly taken up by APCs. The adjuvanticity of PEI relies on the release of host double-stranded DNA and Irf3 signal pathway.\(^{96}\)

**Agonists of pattern recognition receptors**

Ligands for PRRs are the most frequently used molecular adjuvants that are considered as conserved PAMPs.\(^{97}\) PRRs are located on the cell surface or in the cytoplasm, including TLR, STING, nucleotide-binding and oligomerization domain-1 (NOD-1) like receptors (NLR), retinoic acid inducible gene I (RIG-I) etc. TLR agonists constitute a major category of nasal adjuvants. For instance, the commercial synthetic bacterial DNA, IC31, and other CpG oligonucleotides are common mucosal adjuvants that act through the TLR9 signaling pathway.\(^{5,98}\) Poly I:C is a synthetic double-stranded viral RNA that activates TLR3 in macrophages and DCs to induce durable and protective T cell responses.\(^{99}\) Rintatolimod, a modified form of poly I:C, was reported to be well-tolerated as the adjuvant for a trivalent influenza vaccine in a phase I clinical trial.\(^{100}\) A mixture of CpG and Poly I:C was proven to be a safe and effective nasal adjuvant for a COVID-19 subunit vaccine in rhesus macaques since no vaccine-induced immune pathology was observed even after 3–4 doses.\(^{101}\) Lipopolysaccharide (LPS) is a classic agonist of TLR4 and an effective mucosal adjuvant.\(^{102}\) But the potential toxicity of LPS significantly limited its application in humans. Thus, a low-toxicity derivative of LPS was produced: MPL.\(^{103}\) Clinical trials have verified the safety and efficacy of MPL as an IN adjuvant for a norovirus vaccine (NCT00806962, NCT00973284). Flagellin is a protein-based vaccine carrier and adjuvant which could activate TLR5. IN immunization with flagellin-adjuvanted influenza virus subunit vaccine induced significantly stronger antiviral immunity than naked antigen in chickens.\(^{104}\) Imidazoquinolines-based TLR7/TLR8 agonists are also attractive nasal adjuvants owing to their high safety profile and effectiveness.\(^{104}\)

Bacterial second messengers, including cyclic dinucleotides (e.g., c-di-AMP and c-di-GMP) are representatives of novel mucosal adjuvants.\(^{6}\) They activate the STING pathway to produce IFN-I and further induce adaptive immune response.\(^{105}\) IN vaccination with recombinant Tc52 or its amino-terminal domain combined with c-di-AMP adjuvant triggered Th17-specific immunity and protected mice against *Trypanosoma cruzi* infection.\(^{106}\) A COVID-19 vaccine successfully incorporated S protein antigen and a commercial agonist of STING, 2′-3′ cyclic guanosine monophosphate adenosine monophosphate (cGAMP), into liposomes for IN immunization.\(^{72}\) A mixed adjuvant composed of various TLR agonists (CpG (TLR9), LP1569 (TLR2)) and c-di-GMP induced IL-17-secreting T\(_{h17}\) BM cells after IN immunization, which were responsible for sustained protective immunity against *Bordetella pertussis* nasal colonization.\(^{107}\) RIG-I can detect endogenous and exogenous RNA to initiate innate antiviral immunity.\(^{108}\) Jangra et al. successfully integrated an RNA agonist of RIG-I (IVT Dl) with a nanoemulsion (an activator of TLRs and NLRP3) as the adjuvant for an S protein antigen of SARS-CoV-2.\(^{72}\) Nevertheless, it must be noted that PRR-based adjuvants may cause severe effects on developing fetuses.\(^{109}\) Thus, PRR agonist adjuvant-based vaccines should be used with careful evaluation in special populations like pregnant women.

**Cytokines**

Numerous cytokines have been added to enhance the immune responses of IN vaccines, owing to their intrinsic characteristics of activating and regulating adaptive immunity. For instance, IL-15 was used as the adjuvant in developing an IN subunit vaccine against SARS-CoV-2 infection in rhesus macaques.\(^{73}\) Others cytokines like IL-12, IFN-1, IL-1 family, TNF family, and granulocyte-macrophage colony-stimulating factors are also frequently used as IN adjuvants.\(^{110}\) Another review concerning cytokine adjuvants is recommended for readers for more information.\(^{110}\) However, it is worth noting that adverse effects may occur after high-dose and repeated administration of cytokine-containing vaccines.

**Others**

α-GalCer is an activator of the invariant natural killer T cells and a promising IN adjuvant. The presentation of α-GalCer is dependent on CD1d molecule expressed on APCs.\(^{111}\) It is most frequently used in the generation of IN vaccines of influenza virus to induce strong and long-lasting protective immunity.\(^{112,113}\) Of note, two analogs of α-GalCer with improved solubility, KBC-007 and KBC-009, were developed as safe and effective IN adjuvants for inactivated influenza virus vaccine.\(^{113}\) Recent studies showed that the first licensed aluminum salts are potentially tolerable nasal adjuvants and can help elicit antiviral immunity systemically and locally at multiple mucosal sites.\(^{114,115}\) Apart from the adjuvants mentioned above, some other synthetic small organic molecules (e.g., compound 48/80, vitamin E TPGS) and natural molecules (e.g., saponins and lipids) have been successfully used as IN adjuvants in experimental settings. Readers are recommended to refer to another review of this section\(^{116}\) if interested.
Potential delivery devices for intranasal vaccines

Various devices can be developed to deliver IN vaccines, including pipette droppers and spray devices with different operational mechanisms. The conventional pipette-based delivery method, in which the vaccines are dropped into the nostrils, is unspecific and unstandardized, with drug volumes easily exceeding the nasal cavity volume. A variety of spray devices have dominated the nasal delivery market due to their excellent performance in cost and clinical efficacy. Spray devices can be designed to achieve an optimal mean particle size. For instance, the only approved nasal vaccine FluMist® used AccuSpray Device that consists of a single-use pre-filled syringe to produce large particles, leading to decreased vaccine deposition into lower airways and reduced side effects. Metered-dose spray pumps are most studied for vaccines, which are portable, easy to use, self-contained, and safe. They can be actuated via hand press, breath, or electrical power. It is reported that intranasal vaccination of Shigella antigens with a spray device (Dolphin™) induced significantly higher plasma and antibody-secreting cell immune responses than pipette delivery of the same dose of antigens. The intranasal Ad5-nCoV vaccine utilized the advanced Aerogen Ultra Device, which could produce numerous homogeneous small particles with vibrating net technology. However, the wide use of metered-dose spray devices is limited by drug waste caused by residues in the devices and drug leakage during vaccination which is environment-unfriendly.

Safety of intranasal vaccines

IN vaccines can be developed based on multiple vaccine platforms, e.g., viral vectors and protein subunit vaccines. An essential consideration for IN vaccine development is safety. There are some concerns about whole pathogen-based vaccines due to the possibility of reversion into replicating state. Meanwhile, adjuvants are essential for strong immune responses, especially for protein subunit vaccines. But safety problems can also arise along with the addition of adjuvants owing to their immunomodulatory properties. Another alarming problem for IN vaccines is the possibility of retrograde transport to the brain via olfactory nerves, which has been observed in live attenuated adenovirus. In developing IN COVID-19 vaccines, increasing numbers of preclinical studies have proven their safety profiles. For instance, Sui et al. reported no observation of vaccine-induced immune pathology even after 3 or 4 doses in rhesus macaques. Other vaccine candidates, including a lentivirus-vectorized vaccine, a chimpanzee adenovirus-vectorized vaccine, and a PIV5-based vaccine, were all demonstrated to be highly tolerable after IN dose in different animal models. Nevertheless, long-term observation and more clinical data are required to prove the safety of those IN vaccines.

Conclusion and perspectives

IN vaccine is a promising preventive strategy for SARS-CoV-2 considering the remarkable protective immunity in the mucosal sites. Although all the licensed mucosal vaccines are based on whole pathogens, the investigation of IN COVID-19 vaccines predominantly focused on safer vaccine platforms, especially viral vectors and protein subunits. Nevertheless, the poor immunogenicity and stability of highly pure subunit antigens require the application of mucosal adjuvants and delivery systems to overcome the harsh mucosal barriers and enhance immune responses. Avoiding nasal clearing is one of the biggest challenges in the development of IN vaccines. Current studies have demonstrated that IN immunization with different types of COVID-19 vaccines induced robust protective immunity in animal models. The promising results tremendously promoted their evaluation in clinical trials. However, we still know little about how the mucosal and systemic immune responses are triggered by IN immunization with various vaccines. Furthermore, tremendous efforts are necessary to develop desirable mucosal adjuvants and delivery systems with high effectiveness and tolerability to efficiently deliver the intact forms of antigens towards target cells. Finally, there may be ethical considerations of immunization with IN COVID-19 vaccines without IM protection. Since IN vaccines exhibit plenty of advantages over IM vaccines as discussed in the earlier section, we should popularize the public about IN vaccines’ features and immune mechanisms, and offer the general public a choice of the immunization methods. In a word, IN immunization route can induce sterilizing mucosal and systemic immunity, further preventing virus infection and transmission. Application of IN vaccines will hopefully help deal with the persistent COVID-19 pandemic and potential viral contagious diseases in the future.

Outstanding questions

To further optimize the potential values of IN vaccines of SARS-CoV-2 and promote their translation into clinic, there remains a lot to be done, including:

1. More precise mechanisms of how IN vaccines activate the mucosal and systemic immune responses need to be clarified, such as how different types of antigens are processed by various immune cells of the respiratory system; how diverse components of the IN vaccines, like adjuvants, affect the induction of immune responses.
2. While ensuring the efficacy of IN vaccines, how to seek an adoptable scale-up strategy of the manufacturing process to make COVID-19 vaccines available for wide-scale use before the pandemic ends.

3. It is necessary to develop ideal mucosal adjuvants and delivery systems that can guarantee the efficacy and safety of IN vaccine at the same time. Moreover, these adjuvants and delivery systems are best to be simple in composition, stable in activity, easy for manufacturing, and of low cost.

**Search strategy and selection criteria**

Data for this review were identified by searches of PubMed and Web of Science, and references from relevant articles using the search terms “SARS-CoV-2”, “COVID-19”, “vaccine”, “IN”, “mucosal”, “immunization”, “adjuvant”, and “delivery”. Only articles published in English were included up to 24 November 2021. Data from WHO (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines), COVID-19 vaccine tracker (https://covid19.trackvaccines.org/) and clinical trial.gov (https://clinicaltrials.gov/) were also included.

**Contributors**

Xiawei Wei contributed to the conception and design of the review. The first draft of the manuscript was written by Aqu Alu and Li Chen. Aqu Alu, Li Chen and Hong Lei created all the figures and tables. Yuquan Wei and Xiaohe Tian critically revised the manuscript. All authors contributed to the article and approved the submitted version.

**Declaration of interests**

The authors declare that they have no conflicts of interests.

**Acknowledgements**

This work was supported by the National Natural Science Foundation Regional Innovation and Development (No. U19A2003), the National Science Foundation for Youth Foundation of the Sichuan Scientific Committee (No. U19A2003), the National Science Foundation for Regional Innovation and Development (No. U19A2003), the National Science Foundation for Youth Foundation of the Sichuan Scientific Committee (No. U19A2003), the National Science Foundation for Regional Innovation and Development (No. U19A2003), the National Science Foundation for Youth Foundation of the Sichuan Scientific Committee (No. U19A2003), the National Science Foundation for Regional Innovation and Development (No. U19A2003). The funders had no role in paper design, data collection, data analysis, and interpretation, and writing of the paper.

**References**

1. WHO’s landscape of COVID-19 vaccine candidates. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines, 24-November 2021.
2. Registry data of COVID-19 vaccine candidates. https://covid19.trackvaccines.org/, 24-November 2021.
3. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205-211.
4. Tithoni M, Casetari L, Ilham L. Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines? Int J Pharm. 2021;603:126868.
5. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369(6510):1501–1505. (New York, NY).
6. Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 2015;6(7):480–503.
7. Lavelle EC, Ward RW. Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol. 2021.
8. Park JH, Lee HK. Delivery routes for COVID-19 vaccines. Vaccines. 2021;9(5):524. (Basel).
9. Chavda VP, Vora LK, Pandya AK, Patrawale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(12):2619–2636.
10. Kyd J. Immunity against mucosal pathogens. Hum Vaccin Immunother. 2010;6 (1):10016.
11. Villena J, Kitazawa H. The modulation of mucosal antiviral immunity by immunobiotics: could they offer any benefit in the SARS-CoV-2 pandemic? Front Physiol. 2020;11:699.
12. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2002;8(1):545–553.
13. Yuan Q, Walker WA. Innate immunity of the gut: mucosal defense in health and disease. J Pediatr Gastroenterol Nutr. 2004;38(4):461–473.
14. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccin Immunother. 2020;16 (12):2921–2931.
15. Moradil-Kalbaljani S, Maji-dzadeh AK, Abdolvahab MH, Jalili N, Farahmand L. The role of mucosal immunity and recombinant probiotics in SARS-CoV-2 vaccine development. Probiotics Antimicrob Proteins. 2021;13(3):1235–1253.
16. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):673–686.
17. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol. 2008;8 (12):911–922.
18. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;8(1):1093–1105.
19. Kurtovic L, Beson JG. Complement factors in COVID-19 therapeutics and vaccines. Trends Immunol. 2021;42(2):94–103.
20. Li Y, Jin L, Chen T. The effects of secretory IgA in the mucosal immune system. Biomed Res Int. 2020;2020:210257.
21. Tacchi L, Musharrafieh R, Larragote ET, et al. Nasal immunity is an ancient arm of the mucosal immune system of vertebrates. Nat Commun. 2014;5:2105.
22. Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010;8(9):656–667.
23. Curthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2015;4:185.
24. Rogier EW, Frantz AL, Bruno ME, Kaetzel CS. Secretory IgA is concentrated in the outer layer of colonic mucus along with gut bacteria. Pathogens. 2014;3(2):390–403.
25. Nurkic J, Umanov I, Armautalic L, Thic N, Halilovic D, Jahic M. Diagnostic significance of reduced IgA in children. Med Arch. 2014;68(6):381–383.
26. Fischer A. Resistance of children to COVID-19. How? Mucosal Immunol. 2020;13(4):653–655.
27. Rakha K, Abraham W, Wang C, et al. Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells. Sci Immunol. 2021;6(55):eaby86001.
28. Slutter B, Pewe LL, Kaeck SM, Hart HJ. Lung airway-surveillance CXCR3hi memory CD8+ T cells are critical for protection against influenza A virus. Immunity. 2013;39(5):939–948.
29. Uddback I, Kartwight EK, Scholler AS, et al. Retrograde migration strategies of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369(6510):1501–1505. (New York, NY).
30. Stolley JM, Johnston TS, Soeren AG, et al. Retrograde migration supplies resident memory T cells to lung-draining LN after influenza infection. J Exp Med. 2020;217(8):e2019297.
31. Swarnalekha N, Schreiner D, Listler LC, et al. Resident helper cells promote humoral responses in the lung. Sci Immunol. 2021;6 (55).
Son YM, Cheron IS, Wu Y, et al. Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Sci. Immunol. 2021;6(62):eabm6681.

Hassan AO, Kafai NM, Dmitriev IP, et al. A single-dose intranasal ChAdOx1 nCoV-19 vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2022;189(6):1685–1694.e13.

Du Y, Xu Y, Feng J, et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mice. Vaccine. 2021;39(6):2820–2827.

Bricker TL, Darling TL, Harmon AO, et al. A single intranasal or intramuscular immunization with the chimpanzee adenovirus-vectorised SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 2021;36(5):109400.

Ljek BS, Luque SL, Liu Q, Parker D, Bae T, Weiser JN. Protection from the acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase. Proc Natl Acad Sci USA. 2012;109(43):17823–17828.

Safdar M, Kumar GS, Savarir C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233(4768):1081–1084. (New York, NY).

Wu S, Zhang G, Zhang J, et al. A single dose of an adenovirus-vectorised vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4581.

Feng L, Wang Q, Shan C, et al. An adenovirus-vectorised COVID-19 vaccine protects against COVID-19 in rhesus macaques. Nat Commun. 2020;11(1):4207.

Zhu K, An Y, Li Q, et al. Recombinant chimpanzee adenovirus AdC7 vaccine protects against SARS-CoV-2 variants by a lentiviral vector against SARS-CoV-2. EMBO Mol Med. 2021;13(3):e14459.

Rice A, Verma M, Shin A, et al. Intranasal vaccination with a Newcastle disease virus-vectorised SARS-CoV-2 variant demonstrates preclinical safety and efficacy. Vaccine. 2021;39(12):109441.

Lara-Puente JH, Carreño JM, Sun W, et al. Safety and immunogenicity of a newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX/Covid-12-HEXAPRO (Patria), in pigs. mBio. 2021;12(3):e01985-21.

Sun W, Liu Y, Amanat F, et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun. 2021;12(1):6197.

Warner BM, Santy IA, Leacy A, et al. Intranasal vaccination with a Newcastle disease-virus-vectorised vaccine protects hamsters from SARS-CoV-2 infection and disease. iScience. 2021;24(1):103149.

Park JG, Oladunni FS, Rohaim MA, et al. Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. iScience. 2021;12(4):109441.

Li H, Zhang Y, Li D, et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct Target Ther. 2021;6(1):58.

OD KL, Clancy CS, Griffin AJ, et al. Optimization of single dose VSV-based COVID-19 vaccination in hamsters. bioRxiv. 2021.

Furuyama W, Shifflett K, Pinskni AN, et al. Rapid protection from COVID-19 in nonhuman primates vaccinated intranasally but not intranasally with a single dose of a recombinant vaccine. bioRxiv. 2021.

Altmunne announces update on AdCovIDTM phase 1 clinical trial. https://www.globenewswire.com/news-release/2021/06/29/2255175/9/en/Altmunne-Announces-Update-on-AdCovID-TM-Phase-1-Clinical-Trial.html, 24 November 2021.

Chern J, Wang P, Yuan L, et al. A live attenuated influenza virus-vectorised intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 infection. bioRxiv. 2021.

Karch CP, Burkhard P. Vaccine technologies: from whole organims to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–14.

Lee H, Ahu A, Yang J, et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):291.

Jangra S, Landers JJ, Rathnasinghe R, et al. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine. Front Immunol. 2021;12:72355.

An X, Martinez-Paniagua M, Rezvan A, et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience. 2021;4(3):10307.

Kim YI, Kim D, Yu KM, et al. Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets. mBio. 2021;12(2):e00230–21.

Sui Y, Li J, Zhang R, et al. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight. 2021;6(10):e148494.

Kim YI, Kim SG, Kim SM, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020;27(3):704–709. e2.

Jing Y, Run-Qian L, Hao-Ran W, et al. Potential influence of COVID-19/ACE2s on the female reproductive system. Mol Hum Reprod. 2020;26(6):367–373.

See SH, Jang Y. Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection. Vaccines. 2020;8(4):58.

Wang Y, Yang C, Song Y, et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci USA. 2021;118:29(2):e210277118.

Jia Q, Bielefeldt-Ohmann H, Maison RM, et al. Replicating bacteriunm-vectorised vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. NPJ Vaccines. 2021;6(1):47.
87 Bernasconi V, Norling K, Gribonika I, et al. A vaccine combination
88 Eriksson AM, Sch
93 Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N.
95 Mills KH, Cosgrove C, McNeela EA, et al. Protective levels of diph-
98 Wizel B, Persson J, Th
82 Wu M, Zhao H, Li M, Yue Y, Xiong S, Xu W. Intranasal vaccination
80 Kumar US, Afjei R, Ferrara K, Massoud TF, Paulmurugan R. Gold-
83 Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery
117 Riddle MS, Kaminski RW, Williams C, et al. Safety and immunoge-
116 Xu H, Cai L, Hufnagel S, Cui Z. Intranasal vaccine: factors to con-
114 Thakkar SG, Warnken ZN, Alzhrani RF, et al. Intranasal immuni-
115 Chandel A, Goyal AK, Ghosh G, Rath G. Recent advances in aero-
113 Lee YS, Lee KA, Lee JY, et al. An
108 Xu XX, Wan H, Nie L, Xiang X, Shao JZ, RIG-I: a multi-
106 Matos MN, Cazorla SI, Schulze K, Ebensen T, Guzm
104 Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An
101 Bal SM, Sliter B, Verheul R, Bounstra JA, Jiskoot W. Adjuvanted,
100 Overton ET, Goepfert PA, Cunningham P, et al. Intranasal sea-
105 Bal SM, Sliter B, Verheul R, Bounstra JA, Jiskoot W. Adjuvanted,
107 Bal SM, Sliter B, Verheul R, Bounstra JA, Jiskoot W. Adjuvanted,
102 Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the
109 Xu XX, Wan H, Nie L, Xiang X, Shao JZ, RIG-I: a multi-
110 Wang X, Meng D. Innate endogenous adjuvants prime to desirable
111 Wang X, Meng D. Innate endogenous adjuvants prime to desirable
112 Wang X, Meng D. Innate endogenous adjuvants prime to desirable
119 Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the
118 Wang X, Meng D. Innate endogenous adjuvants prime to desirable
116 Xu H, Cai L, Hufnagel S, Cui Z. Intranasal vaccine: factors to con-
40 www.thelancet.com Vol 76 Month February, 2022
Review